In vivo gene therapy of malignant tumours with heat shock protein-65 gene

Gene Therapy
K V LukacsM J Colston

Abstract

We have previously shown that ex vivo insertion of a gene encoding the mycobacterial heat shock protein-65 into tumour cells results in their inability to form tumours in mice. We report regression of highly malignant reticulum cell sarcomas (J774) after liposome-mediated gene transfer in vivo. Heat shock gene transfer resulted in tumour regression both in immunocompetent and immunodeficient SCID mice. Complete tumour eradication, however, was detected only in immunocompetent animals, confirming the role of T cells in tumour rejection. Treatment of tumour bearing mice with the heat shock gene-liposome complex resulted in the production of antibodies against the tumour cells, indicating an increase in the antigenicity of the tumour after gene transfer. These results suggest that the heat shock protein-65 gene could provide a novel approach for the treatment of established tumours.

Citations

Feb 13, 2001·The International Journal of Biochemistry & Cell Biology·K Trieb, R Kotz
May 4, 2001·Anti-cancer Drugs·A G Schatzlein
Jan 26, 1999·Annals of the New York Academy of Sciences·P L Moseley
May 8, 1999·Lancet·K V Lukacs, M G Davies
May 20, 2000·Biotechnology & Genetic Engineering Reviews·A R CoatesP Mascagni
Jun 2, 2009·FEMS Immunology and Medical Microbiology·Mohammed Nadeem KhanGovindaswami Ilavazhagan
May 29, 2007·American Journal of Physiology. Lung Cellular and Molecular Physiology·Arnon ElizurRobert M Senior
Sep 5, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Luis Sanchez-PerezRichard G Vile

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.